New hope for rare thymus cancers: PT-112 trial launches

NCT ID NCT05104736

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called PT-112 in people with thymoma or thymic cancer that has come back or worsened after standard treatment. PT-112 is designed to kill cancer cells and boost the immune system. About 53 adults will receive the drug intravenously in 28-day cycles. The main goal is to see if tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PT-112
What this could lead to: If successful, PT-112 could offer a new treatment option for people with recurrent thymoma or thymic carcinoma, potentially shrinking tumors and delaying disease progression.
What could go wrong: This is an early Phase 2 trial with only 53 participants, so results may not apply to everyone. PT-112 may cause side effects, and there is no guarantee it will work better than existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT THYMOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

peripheral nervous system disorder thymic carcinoma thymic epithelial neoplasm thymoma thymus cancer Thymus Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT THYMOMA THYMIC CANCER THYMIC EPITHELIAL TUMOR

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.